Alain Attia
Overview
Explore the profile of Alain Attia including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
798
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lacombe K, Moh R, Chazallon C, Lemoine M, Sylla B, Fadiga F, et al.
Sci Rep
. 2024 May;
14(1):10244.
PMID: 38702350
Access to Hepatis C treatment in Sub-Saharan Africa is a clinical, public health and ethical concern. The multi-country open-label trial TAC ANRS 12311 allowed assessing the feasibility, safety, efficacy of...
2.
Plaisy M, Minga A, Wandeler G, Murenzi G, Samala N, Ross J, et al.
J Int AIDS Soc
. 2024 Apr;
27(4):e26238.
PMID: 38566493
Introduction: Liver disease is a leading cause of morbidity and mortality among persons living with HIV (PLHIV). While chronic viral hepatitis has been extensively studied in low- and middle-income countries...
3.
Marcellin F, Mourad A, Lemoine M, Kouanfack C, Seydi M, Carrieri P, et al.
JHEP Rep
. 2023 Jan;
5(3):100665.
PMID: 36686592
Background & Aims: Patient-reported outcomes (PROs) are poorly documented for patients with chronic hepatitis C on direct-acting antiviral (DAA) treatment in low-to-middle-income countries. We documented PROs during and after DAA...
4.
Boyer S, Baudoin M, Nishimwe M, Santos M, Lemoine M, Maradan G, et al.
BMC Health Serv Res
. 2022 Mar;
22(1):303.
PMID: 35248039
Background: Although direct-acting antivirals (DAA) have become standard care for patients with chronic hepatitis C worldwide, there is no evidence for their value for money in sub-Saharan Africa. We assessed...
5.
Duchesne L, Hejblum G, Njouom R, Toure Kane C, Toni T, Moh R, et al.
PLoS One
. 2020 Aug;
15(8):e0238035.
PMID: 32833976
Background: Whereas 72% of hepatitis C virus (HCV)-infected people worldwide live in low- and middle-income countries (LMICs), only 6% of them have been diagnosed. Innovative technologies for HCV diagnosis provide...
6.
Baudoin M, Woode M, Nishimwe M, Lemoine M, Sylla B, Kouanfack C, et al.
Liver Int
. 2020 Jul;
40(11):2643-2654.
PMID: 32687669
Background: In Sub-Saharan Africa, chronic hepatitis C (CHC) is a major public health issue. We estimated the long-term clinical benefits of treating CHC with sofosbuvir-based regimens in Cameroon, Côte d'Ivoire...
7.
Duchesne L, Hejblum G, Toure Kane N, Njouom R, Toni T, Moh R, et al.
Int J Drug Policy
. 2019 Dec;
75:102613.
PMID: 31786434
Background: Scaling-up the access to hepatitis C virus (HCV) diagnostics for people who use injecting drugs (PWID) is essential to reduce the HCV incidence in low and middle-income countries. Methods:...
8.
Seri B, Minga A, Gabillard D, Dembele B, Konate S, Le Carrou J, et al.
Open Forum Infect Dis
. 2018 Apr;
5(4):ofy060.
PMID: 29644251
Background: Hepatitis B virus (HBV) and human immunodeficiency virus (HIV) share common risk factors. The parallel description of their frequency over time may help capture their similarities and differences. Methods:...
9.
Didi-Kouko Coulibaly J, Yeboua M, MBengue A, Kouadio E, Anzouan-Kacou Kissi H, Binan A, et al.
Bull Cancer
. 2018 Feb;
105(3):329.
PMID: 29459091
No abstract available.
10.
Boa A, Douba A, N Guessan T, Menan H, Attia A, Ouassa T, et al.
Sante Publique
. 2018 Feb;
29(5):751-760.
PMID: 29384309
The Côte d'Ivoire National Immunization Technical Advisory Group 2015 work plan included elaboration of an opinion on inclusion of hepatitis B vaccination at birth in the Expanded Program on Immunization...